Innovent Biologics’ experimental weight-loss drug achieves breakthrough in Phase 3 trial
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
Conjugated Estrogens Tablets are indicated for moderate to severe menopausal symptoms, including hot flashes, and for the prevention of postmenopausal osteoporosis in women at significant risk
Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
Uncontrolled diabetes in pregnancy dramatically increases the risk of pre-eclampsia, stillbirth, birth injuries, and long-term cardiometabolic diseases
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Diversifying its portfolio to include late-phase antiviral agent
Subscribe To Our Newsletter & Stay Updated